Those inhibitors have good anti-proliferative effects against breast cancer (MCF-7), hepatocellular carcinoma (HepG-2), colorectal carcinoma (HCT-116), and non-small cell lung cancer cells (A549) and exhibited EGFR inhibitory action32. Here, EGFR is linked to breast cancer.